Saint Luke’s Mid America Heart Institute today announced results from the STEP HFpEF DM trial.
— Read on www.saintlukeskc.org/about/news/semaglutide-24-mg-demonstrates-large-reductions-heart-failure-related-symptoms-and
Semaglutide 2.4 mg Demonstrates Large Reductions in Heart Failure Related Symptoms and Physical Limitations in People with Obesity-Related Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes | Saint Luke’s Health System
★★★★★
